Staging and management of cutaneous T-cell lymphoma.
Cutaneous T-cell lymphoma (CTCL) accounts for two-thirds of cases of primary cutaneous lymphoma. Most variants of CTCL are indolent lymphoma, the most common being mycosis fungoides. In addition, Sézary syndrome, the leukaemic variant, has an aggressive clinical course. Accurate diagnosis and staging is critical in determining the prognosis of those with CTCL. The tumour, node, metastasis and blood stage needs to be documented and used to determine an overall stage from IA to IVB. Management of patients should be carried out by a multidisciplinary team. A full clinical examination should be made at all visits. Thorough investigations are needed at diagnosis and should be repeated during disease progression to allow initial staging and restaging. Treatment of patients with early-stage disease (IA-IIB) should be limited to skin-directed therapy. More advanced or resistant disease may be treated with systemic therapies such as extracorporeal photopheresis, immunotherapy, monoclonal antibody therapy, novel retinoids or chemotherapy, and where possible, patients should be entered into clinical trials.
St John's Institute of Dermatology, St Thomas's Hospital, London, UK. juliascarisbrick@doctors.net.uk
J J
JJ
Scarisbrick
D000970:Antineoplastic Agents / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000379:methods; D003879:Dermatologic Agents / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D016410:Lymphoma, T-Cell, Cutaneous / Q000473:pathology* / Q000628:therapy; D009182:Mycosis Fungoides / Q000473:pathology / Q000628:therapy; D009367:Neoplasm Staging / Q000379:methods*; D017893:Photopheresis / Q000379:methods; D010789:Phototherapy / Q000379:methods; D012751:Sezary Syndrome / Q000145:classification / Q000473:pathology / Q000628:therapy; D012878:Skin Neoplasms / Q000473:pathology / Q000628:therapy
D000970:Antineoplastic Agents; D003879:Dermatologic Agents